Sanofi's Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck can eventually match its success remains to be seen, but the pair is now one step closer to finding out.
As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer by the end of the year.
The latest pharma company to wind up in the middle of insider trading charges? Merck. A former employee at the drug giant has been charged after allegedly tipping off a former classmate about potential deals that scored him $683,000.
This summer, as Merck inched closer and closer to its $3.9 billion buyout of Idenix Pharmaceuticals, one of the company's employees tipped off a friend that a deal was imminent, federal prosecutors say. With that information, the pair made hundreds of thousands of dollars on insider trades, according to the SEC, the latest scandal for an industry increasingly vulnerable to such manipulation.
With report after report finding flaws in the data security practices of healthcare and life science organizations, Exostar has decided to accelerate its expansion into the sector. And the company has snagged funding from the Merck Global Health Innovation Fund to support its plans.
Accenture has joined with some big names for its R&D analytics platform. Eisai, Merck and Pfizer have signed up to collaborate on further development of the system, which is built on a mix of technologies from Accenture and Oracle.
The sex discrimination lawsuit against Merck lives on. A federal judge refused to toss out the $250 million suit, which claims that female sales reps were paid less, promoted less and ignored when they complained about it.
Merck's marketing team is adding another arrow to its quiver of community-oriented campaigns: a partnership with HBCU Connect, a niche media network targeting alumni and students of historically black colleges and universities.
You can't accuse Merck & Co. of ignoring diversity. The drugmaker's marketing team is adding another arrow to its quiver of community-oriented campaigns: A partnership with HBCU Connect, a niche media network targeting alumni and students of historically black colleges and universities.
According to new research, Merck's investigational, 9-valent HPV vaccine has the potential to block about 90% of invasive cervical cancer cases worldwide. But realizing that potential will be no piece of cake.